When will Sparsentan be launched? Has it been launched in China?

Sparsentan received accelerated approval for marketing from the USFDA on202322month17. It is not currently available in China. Sparsentanis a dual endothelin and angiotensinII receptor antagonist, with accelerated approval in 202320232 months based on proteinuria reduction. The U.S. FDA has approved the use of sparsentan to reduce proteinuria in adults with primary immunoglobulinAnephropathy (IgAN) who are at risk for rapid disease progression.

Sparsentanreduced proteinuria to a greater extent than irbesartan. In addition, this is the first non-immunosuppressive therapy used to reduceIgANproteinuria, and usesparsentanmay result in hepatotoxicity and embryo-fetal toxicity. Sparsentanis a dual endothelin and angiotensinII receptor antagonist. At week 36, within the range of observed sparsenstatexposures, sparsenstatexposure was associated with the urinary protein-to-creatinine ratio (U The exposure-response (E-R) relationship between percent decrease from baseline in PCR) was not statistically significant. The E-Rrelationship was not statistically significant for any grade of hypotension or for the most severe grade of peripheral edema. In healthy subjects, sparsentan caused QTcF prolongation at 800 mg and 1600 The maximum average effects of mg were 8.8ms and 8.1ms respectively. The mechanism behind the observed QTc prolongation is unclear but is unlikely to be mediated by direct inhibition of hERG channels. At recommended doses, clinically relevantQTc is not expected to occurExtended. Use of sparsentanmay result in hepatotoxicity, embryo-fetotoxicity, hypotension, acute kidney injury, hyperkalemia, and fluid retention. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.